Universe Pharmaceuticals Inc - Understand $upc stock

$UPC Market Cap: $2.814 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$61.13M

TTM

Gross Margin

35.15%

TTM

Net Earnings

-$29.73M

TTM

Current Assets

$33.53M

Q1 2024

Current Liabilities

$20.61M

Q1 2024

Current Ratio

162.69%

Q1 2024

Total Assets

$49.43M

Q1 2024

Total Liabilities

$22.69M

Q1 2024

Book Value

$26.74M

Q1 2024

Cash

P/E

-0.09464

Nov 29, 2024 EST

Free Cash Flow

-$8.853M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018
Revenue	$32.31M	$40.14M	$47.98M	$30.70M	$33.23M	$28.51M
YoY Change	-19.52%	-16.34%	56.27%	-7.6%	16.56%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018
Revenue	$32.31M	$40.14M	$47.98M	$30.70M	$33.23M	$28.51M
Cost Of Revenue	$21.99M	$18.25M	$22.66M	$16.61M	$19.56M	$15.11M
Gross Profit	$10.32M	$21.89M	$25.33M	$14.09M	$13.67M	$13.41M
Gross Profit Margin	31.93%	54.53%	52.78%	45.9%	41.14%	47.04%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018
Selling, General & Admin	$8.983M	$21.69M	$6.098M	$3.070M	$2.830M	$2.730M
YoY Change	-58.57%	255.63%	98.61%	8.49%	3.66%
% of Gross Profit	87.09%	99.06%	24.08%	21.78%	20.7%	20.36%
Research & Development	$4.859M	$7.644M	$5.447M	$567.2K	$600.0K	$760.0K
YoY Change	-36.44%	40.34%	860.29%	-5.46%	-21.05%
% of Gross Profit	47.1%	34.92%	21.51%	4.02%	4.39%	5.67%
Depreciation & Amortization	$508.8K	$533.9K	$446.9K	$410.1K	$420.0K	$450.0K
YoY Change	-4.71%	19.48%	8.97%	-2.36%	-6.67%
% of Gross Profit	4.93%	2.44%	1.76%	2.91%	3.07%	3.36%
Operating Expenses	$13.84M	$29.33M	$11.74M	$3.842M	$3.660M	$3.750M
YoY Change	-52.81%	149.92%	205.46%	4.98%	-2.4%
Operating Profit	-$3.527M	-$7.439M	$13.59M	$10.25M	$10.01M	$9.660M
YoY Change	-52.59%	-154.74%	32.56%	2.41%	3.62%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018
Interest Expense	$156.8K	$162.4K	-$70.77K	-$101.9K	-$100.0K	-$140.0K
YoY Change	-3.46%	-329.48%	-30.58%	1.94%	-28.57%
% of Operating Profit			-0.52%	-0.99%	-1.0%	-1.45%
Other Income/Expense, Net	-$322.8K	-$545.3K	$160.7K	-$49.35K	$0.00	$10.00K
YoY Change	-40.81%	-439.42%	-425.57%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018
Pretax Income	-$3.850M	-$7.984M	$13.68M	$10.10M	$9.650M	$9.520M
YoY Change	-51.78%	-158.37%	35.42%	4.67%	1.37%
Income Tax	$2.313M	$752.4K	$2.359M	$2.542M	$2.100M	$1.920M
% Of Pretax Income			17.24%	25.17%	21.76%	20.17%
Net Earnings	-$6.163M	-$8.737M	$11.32M	$7.558M	$7.550M	$7.600M
YoY Change	-29.46%	-177.18%	49.77%	0.11%	-0.66%
Net Earnings / Revenue	-19.08%	-21.76%	23.59%	24.62%	22.72%	26.66%
Basic Earnings Per Share	-$1.70	-$0.40	$0.60	$0.47
Diluted Earnings Per Share	-$1.70	-$0.40	$596.4K	$359.9K	$359.5K	$361.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018
Cash & Short-Term Investments	$18.50M	$5.711M	$8.078M	$10.06M	$3.180M	$6.190M
YoY Change	223.98%	-29.3%	-19.69%	216.3%	-48.63%
Cash & Equivalents
Short-Term Investments	$13.22M
Other Short-Term Assets	$4.295M	$18.40M	$24.37M	$443.7K	$20.00K	$10.00K
YoY Change	-76.66%	-24.47%	5391.62%	2118.55%	100.0%
Inventory	$3.343M	$2.206M	$2.463M	$1.906M	$2.620M	$8.120M
Prepaid Expenses
Receivables	$10.67M	$15.18M	$15.57M	$10.87M	$6.420M	$7.640M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.81M	$41.51M	$50.48M	$23.28M	$12.23M	$21.96M
YoY Change	-11.31%	-17.78%	116.84%	90.35%	-44.31%
Property, Plant & Equipment	$12.79M	$13.58M	$15.39M	$4.428M	$4.570M	$5.080M
YoY Change	-5.77%	-11.8%	247.64%	-3.11%	-10.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$685.3K	$702.9K	$744.9K	$735.0K	$700.0K	$730.0K
YoY Change	-2.5%	-5.64%	1.35%	5.0%	-4.11%
Other Assets	$2.850M	$3.597M	$3.347M	$186.5K	$170.0K	$140.0K
YoY Change	-20.77%	7.47%	1694.15%	9.73%	21.43%
Total Long-Term Assets	$16.48M	$18.03M	$19.66M	$5.524M	$5.610M	$6.120M
YoY Change	-8.64%	-8.29%	255.94%	-1.53%	-8.33%
Total Assets	$53.29M	$59.54M	$70.14M	$28.80M	$17.84M	$28.08M
YoY Change
Accounts Payable	$4.585M	$3.075M	$5.311M	$2.691M	$1.940M	$2.940M
YoY Change	49.1%	-42.09%	97.33%	38.72%	-34.01%
Accrued Expenses	$2.712M	$2.539M	$444.3K	$376.0K	$550.0K	$620.0K
YoY Change	6.79%	471.52%	18.18%	-31.64%	-11.29%
Deferred Revenue
YoY Change
Short-Term Debt	$5.482M	$7.315M	$4.354M	$3.602M	$2.580M	$2.680M
YoY Change	-25.06%	68.01%	20.86%	39.63%	-3.73%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.75M	$13.10M	$11.21M	$8.001M	$5.450M	$18.40M
YoY Change	5.01%	16.83%	40.11%	46.81%	-70.38%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Total Liabilities	$13.75M	$13.10M	$11.21M	$8.001M	$5.450M	$18.40M
YoY Change	5.01%	16.83%	40.11%	46.81%	-70.38%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	3.625M shares	21.75M shares	18.98M shares	16.00M shares
Diluted Shares Outstanding	3.625M shares	21.75M shares	18.98M shares	16.00M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.8139 Million

About Universe Pharmaceuticals INC

Universe Pharmaceuticals Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Ji'An, Jiangxi and currently employs 225 full-time employees. The company went IPO on 2021-03-23. Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The firm mainly conducts its businesses within the Chinese market.

Industry: Pharmaceutical Preparations Peers: CHINA PHARMA HOLDINGS, INC. China SXT Pharmaceuticals, Inc. SUNWIN STEVIA INTERNATIONAL, INC. BGM Group Ltd.